The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Bioactive pyrrole-based compounds with target selectivity
Open accessAbstract
The discovery of novel synthetic compounds with drug-like properties is an ongoing challenge in medicinal chemistry. Natural products have inspired the synthesis of compounds for pharmaceutical application, most of which are based on N-heterocyclic motifs. Among these, the pyrrole ring is one of the most explored heterocycles in drug discovery programs for several therapeutic areas, confirmed by the high number of pyrrole-based drugs reaching the market. In the present review, we focused on pyrrole and its hetero-fused derivatives with anticancer, antimicrobial, and antiviral activities, reported in the literature between 2015 and 2019, for which a specific target was identified, being responsible for their biological activity. It emerges that the powerful pharmaceutical and pharmacological features provided by the pyrrole nucleus as pharmacophore unit of many drugs are still recognized by medicinal chemists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · cited 1×
“Despite the increasing numbers compared to the 2019 estimation [17], cancer deaths are supposed to decline, indicating that cancer therapy is improving year after year.”
BackgroundVitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Dynamic instability of microtubule growth
Mitchison, T., & Kirschner, M. (1984) · Nature · doi:10.1038/312237a0 · Cited by 3,337 · cited 1×
“Modification of MT dynamics can lead to cell cycle arrest and in consequence to cell death by apoptosis in dividing cells [23].”
BackgroundWu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.008 · Cited by 2,330
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Bioisosterism: A Rational Approach in Drug Design
Patani, G. A., & LaVoie, E. J. (1996) · Chemical Reviews · doi:10.1021/cr950066q · Cited by 1,328
Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,241
The protein tyrosine kinase family of the human genome
Robinson, D. R., Wu, Y.-M., & Lin, S.-F. (2000) · Oncogene · doi:10.1038/sj.onc.1203957 · Cited by 1,167
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A. (2015) · Molecules · doi:10.3390/molecules200916852 · Cited by 716
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01594 · Cited by 643
Heterocycles in drugs and drug discovery
Gomtsyan, A. R. (2012) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-012-0960-z · Cited by 615
Receptor tyrosine kinases: mechanisms of activation and signaling
Hubbard, S. R., & Miller, W. T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.010 · Cited by 531
Chan, K. W., Wong, V. T., & Tang, S. C. W. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500378 · Cited by 398
Current progress in antiviral strategies
Lou, Z., Sun, Y., & Rao, Z. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.006 · Cited by 244
DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents
Raimondi, M. V., Randazzo, O., La Franca, M., Barone, G., Vignoni, E., Rossi, D., & Collina, S. (2019) · Molecules · doi:10.3390/molecules24061140 · Cited by 233
Self-citationClinical advances in the development of novel VEGFR2 inhibitors.
Fontanella, C., Ongaro, E., Bolzonello, S., Guardascione, M., Fasola, G., & Aprile, G. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.08.14 · Cited by 217
The VEGF family in cancer and antibody-based strategies for their inhibition
Sullivan, L. A., & Brekken, R. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11360 · Cited by 181
Role and targeting of anaplastic lymphoma kinase in cancer
Corte, C. M. D., Viscardi, G., Liello, R. D., Fasano, M., Martinelli, E., Troiani, T., Ciardiello, F., & Morgillo, F. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0776-2 · Cited by 155
In-Silico Approaches to Multi-target Drug Discovery
Xiao, H., Shi, Z., Tan, C., Jiang, Y., Go, M., Low, B. C., & Chen, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0065-2 · Cited by 152
Sortase A Inhibitors: Recent Advances and Future Perspectives
Cascioferro, S., Raffa, D., Maggio, B., Raimondi, M. V., Schillaci, D., & Daidone, G. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00779 · Cited by 143
Self-citationWilliams, I. S., Joshi, P., Gatchie, L., Sharma, M., Satti, N. K., Vishwakarma, R. A., Chaudhuri, B., & Bharate, S. B. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.010 · Cited by 60
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents
Whatmore, J. L., Swann, E., Barraja, P., Newsome, J. J., Bunderson, M., Beall, H. D., Tooke, J. E., & Moody, C. J. (2002) · Angiogenesis · doi:10.1023/a:1021528628524 · Cited by 54
Self-citationAntibacterial Drug Discovery: Some Assembly Required
Tommasi, R., Iyer, R., & Miller, A. A. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00027 · Cited by 54
New Synthetic Nitro-Pyrrolomycins as Promising Antibacterial and Anticancer Agents
Raimondi, M. V., Presentato, A., Petri, G. L., Buttacavoli, M., Ribaudo, A., De, V., Alduina, R., & Cancemi, P. (2020) · Antibiotics · doi:10.3390/antibiotics9060292 · Cited by 54
Self-citationJoshi, S. D., Kumar, D., Dixit, S. R., Tigadi, N., More, U. A., Lherbet, C., Aminabhavi, T. M., & Yang, K. S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.025 · Cited by 52
Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators
Corigliano, D. M., Syed, R., Messineo, S., Lupia, A., Patel, R. V., Reddy, C. V. R., Dubey, P. K., Colica, C., Amato, R., Sarro, G. D., et al. (2018) · PeerJ · doi:10.7717/peerj.5386 · Cited by 50
Brindisi, M., Ulivieri, C., Alfano, G., Gemma, S., Balaguer, F. D. A., Khan, T., Grillo, A., Chemi, G., Menchon, G., Prota, A. E., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.004 · Cited by 49
Corona, A., Leva, F. S. D., Rigogliuso, G., Pescatori, L., Madia, V. N., Subra, F., Delelis, O., Esposito, F., Cadeddu, M., Costi, R., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.09.008 · Cited by 44
Maggio, B., Raffa, D., Raimondi, M. V., Cascioferro, S., Plescia, F., Schillaci, D., Cusimano, M. G., Leonchiks, A., Zhulenkovs, D., Basile, L., et al. (2016) · Molecules · doi:10.3390/molecules21020241 · Cited by 40
Self-citationCorona, A., Onnis, V., Deplano, A., Bianco, G., Demurtas, M., Distinto, S., Cheng, Y., Alcaro, S., Esposito, F., & Tramontano, E. (2017) · Pathogens and Disease · doi:10.1093/femspd/ftx078 · Cited by 40
FMS Kinase Inhibitors: Current Status and Future Prospects
El-Gamal, M. I., Anbar, H. S., Yoo, K. H., & Oh, C. (2012) · Medicinal Research Reviews · doi:10.1002/med.21258 · Cited by 37
Kurup, S., McAllister, B., Liskova, P., Mistry, T., Fanizza, A., Stanford, D., Slawska, J., Keller, U. B., & Höllein, A. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1376666 · Cited by 34
Lee, Y. H., Lee, J. M., Kim, S. G., & Lee, Y. S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.054 · Cited by 31
Costa, G., Rocca, R., Corona, A., Grandi, N., Moraca, F., Romeo, I., Talarico, C., Gagliardi, M. G., Ambrosio, F. A., Ortuso, F., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.029 · Cited by 30
A Minimal Model of Signaling Network Elucidates Cell-to-Cell Stochastic Variability in Apoptosis
Raychaudhuri, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011930 · Cited by 29
Cascioferro, S., Maggio, B., Raffa, D., Raimondi, M. V., Cusimano, M. G., Schillaci, D., Manachini, B. R. I., Leonchiks, A., & Daidone, G. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1535-9 · Cited by 25
Self-citationDesign, synthesis and in vitro apoptotic mechanism of novel pyrrolopyrimidine derivatives
Kılıç-Kurt, Z., Bakar‐Ates, F., Aka, Y., & Kütük, Ö. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.060 · Cited by 25
Schillaci, D., Petruso, S., Cascioferro, S., Raimondi, M. V., Haagensen, J. A. J., & Molin, S. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.10.013 · Cited by 20
Self-citationMesaros, E. F., Angeles, T. S., Albom, M. S., Wagner, J. C., Aimone, L. D., Wan, W., Lü, L., Huang, Z., Olsen, M. A., Kordwitz, E., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.019 · Cited by 19
Carta, D., Bortolozzi, R., Sturlese, M., Salmaso, V., Hamel, E., Basso, G., Calderan, L., Quintieri, L., Moro, S., Viola, G., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.026 · Cited by 19
Bortolozzi, R., Carta, D., Prà, M. D., Antoniazzi, G., Mattiuzzo, E., Sturlese, M., Paolo, V. D., Calderan, L., Moro, S., Hamel, E., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.092 · Cited by 17
Bortolozzi, R., Mattiuzzo, E., Prà, M. D., Sturlese, M., Moro, S., Hamel, E., Carta, D., Viola, G., & Ferlin, M. G. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.038 · Cited by 13
Raffa, D., Maggio, B., Plescia, F., Cascioferro, S., Raimondi, M. V., Cancemi, G., D’Anneo, A., Lauricella, M., Cusimano, M. G., Bai, R., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.08.027 · Cited by 12
Self-citationLi, G., Dong, H., Ma, Y., Shao, K., Li, Y., Wu, X., Wang, S., Shao, Y., & Zhao, W. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.017 · Cited by 9
Metadata
- Authors
- Li Petri, G., Spanò, V., Spatola, R., Holl, R., Raimondi, M. V., Barraja, P., & Montalbano, A.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 208
- Pages
- 112783
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W3080502255
- Cited by
- 261
- References
- 46
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.